Health Advocacy Inc. : how pharmaceutical funding changed the breast cancer movement
Record details
- ISBN: 9780774833844 (hardcover)
-
Physical Description:
print
xii, 383 p. ; 24 cm. - Publisher: Vancouver : UBC Press, c2017.
Content descriptions
Bibliography, etc. Note: | Includes bibliographical references (pages [296]-350) and index. |
Formatted Contents Note: | Canada's health policy landscape -- Health advocacy organizations in Canada -- Beginnings of the breast cancer movement -- Advocacy redefined -- The movement fractures over pharma funding -- Pharma funding as the new norm -- Advocacy groups and the continuing struggle over the pharma-funding question. |
Search for related items by subject
Subject: | Patient advocacy -- Canada Breast -- Cancer -- Research -- Canada -- Finance Pharmaceutical industry -- Canada Medical policy -- Canada |
Available copies
- 1 of 1 copy available at Legislative Library.
Holds
- 0 current holds with 1 total copy.
Location | Call Number / Copy Notes | Barcode | Shelving Location | Holdable? | Status | Due Date |
---|---|---|---|---|---|---|
Legislative Library, Vaughan Street | R 727.45 Bat (Text) | 36970100156241 | General Collection | Volume hold | Available | - |
- Baker & Taylor
"Today, most patient groups in Canada are funded by the pharmaceutical industry, raising an important ethical question: Do alliances between patient organizations and corporate sponsors ultimately lead to policies that are counter to the public interest?In this examination of Canada's breast cancer movement from 1990 to 2010, health activist, scholar, and cancer survivor Sharon Batt investigates the relationship between patient advocacy groups and the pharmaceutical industry--and the hidden implicationsof pharma funding for health policy. Health Advocacy, Inc. dissects the alliances between the companies that sell pharmaceuticals and the individuals who use them, drawing links between neoliberalism and corporate financing, and the ensuing threat to thepublic health care system. Batt combines archival analysis, interviews with advocacy and industry representatives, and personal observation to reveal how a reduction in state funding drove patient groups to form partnerships with the private sector. The resulting power imbalance continues to challenge the groups' ability to put patients' interests ahead of those of the industry. Batt's conclusion is unsettling: a once-vibrant movement that encouraged democratic participation in the development of health policy now eerily echoes the demands of the pharmaceutical industry. This thorough account of the shift from grassroots advocacy to Big Pharma partnership defines the struggles and stakes of activism in public health today."-- - Chicago Distribution Center
Health activist, scholar, award-winning journalist, and cancer survivor Sharon Batt investigates the relationship between patient advocacy groups and the pharmaceutical industry as well as the contentious role of pharma funding. Over the past several decades, a gradual reduction in state funding has pressured patient groups into forming private-sector partnerships. This analysis of Canadaâs breast cancer movement from 1990 to 2010 shows that the resulting power imbalance undermined the groupsâ ability to put patientsâ interests ahead of those of the funders. A movement that once encouraged democratic participation in the development of health policy now eerily echoes the demands of the pharmaceutical industry.
- Univ of Washington Pr
Over the past several decades, a gradual reduction in state funding has pressured patient groups into forming private-sector partnerships. Health activist, scholar, award-winning journalist, and cancer survivor Sharon Batt investigates the relationship between patient advocacy groups and the pharmaceutical industry, as well as the contentious role of pharma funding. This analysis of Canadaâs breast cancer movement from 1990 to 2010 argues that the resulting power imbalance undermined the groupsâ ability to put patientsâ interests ahead of those of the funders. A movement that once encouraged democratic participation in the development of health policy now eerily echoes the demands of the pharmaceutical industry.